Why the study?
Does edge-to-edge repair using a MitraClip improve regurgitation and clinical outcomes in a patient with severe systemic atrio-ventricular valve regurgitation after a Mustard operation?
Does edge-to-edge repair using a MitraClip improve regurgitation and clinical outcomes in a patient with severe systemic atrio-ventricular valve regurgitation after a Mustard operation?
Percutaneous edge-to-edge repair using a MitraClip is feasible and can improve clinical and echocardiographic outcomes in patients with severe systemic atrio-ventricular valve regurgitation after a Mustard operation.
Supports MitraClip feasibility for post-Mustard SAVVR; hypothesis-generating pending prospective data.
A 48-year-old who underwent a Mustard operation in 1972 followed by a second cardiac intervention in 1996 for pulmonary venous baffle enlargement and residual baffle leak closure, complicated by recurrent atrial flutter, was admitted to our institution for severe systemic atrio-ventricular valve regurgitation (SAVVR) associated with severely impaired systemic right ventricular (RV) function. After careful preoperative anatomic assessment including three-dimensional transesophageal echocardiography (3DTEE) to define the clipping strategy and computed tomography to optimize the transvenous baffle puncture site, the intervention was performed under general anesthesia, fluoroscopic, and 3DTEE guidance. One XTR MitraClip was successfully implanted, achieving a significant reduction in regurgitation and immediate clinical improvement. The transbaffle puncture was closed using an 8 mm atrial septal defect (ASD) device without residual shunt or obstruction of the venous baffle. Post-operative clinical evaluation showed immediate improvement in the NYHA functional class (from III to II), but the patient presented with recurrent flutter at 1 week after the procedure, which was successfully treated by catheter ablation with another transbaffle approach next to the ASD device. Clinical improvement was maintained at 1- and 6-month follow-up with significant reduction in SAVVR, reduced systemic RV volumes and improved RV ejection fraction. This case demonstrates the feasibility of percutaneous treatment of systemic SAVV in patients with systemic RV after atrial redirection.
No takes yet. Share an insight, caveat, or question.
Iriart et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: